Update
$ImmunityBio(IBRX.US$ ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient For 170,000 Doses Of ANKTIVA
Benzinga· 2 mins ago
ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product
ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually
Coupled with a recent announcement of BCG availability in partnership with the Serum Institute of India (SII), ImmunityBio has large-scale inventory and capacity for BCG
Benzinga· 2 mins ago
ANKTIVA Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product
ImmunityBio's 400,000 square foot GMP fill-finish facility in Dunkirk, New York on track to be completed in 12-18 months with capacity to produce a million vials annually
Coupled with a recent announcement of BCG availability in partnership with the Serum Institute of India (SII), ImmunityBio has large-scale inventory and capacity for BCG
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
